Company Announcements

ORION CORPORATION
MANAGERS’ TRANSACTIONS
5 August 2022 at 11.15 EEST              
        

Orion Corporation: Managers’ transactions – Virve Laitinen

Orion Corporation has received the following disclosure under Market Abuse Regulation (EU) No 596/2014, regarding transactions with shares and linked securities in Orion Corporation made by managers and their closely associated persons.

Orion Oyj - Managers' Transactions
____________________________________________

Person subject to the notification requirement
Name: Virve Laitinen
Position: Other senior manager

Issuer: Orion Oyj
LEI: 74370029VAHCXDR7B745
Notification type: INITIAL NOTIFICATION
Reference number: 18216/4/4
____________________________________________

Transaction date: 2022-08-04
Venue: NASDAQ HELSINKI LTD (XHEL)
Instrument type: SHARE
ISIN: FI0009014377
Nature of the transaction: DISPOSAL

Transaction details
(1): Volume: 4000 Unit price: 47,00 EUR

Aggregated transactions
(1): Volume: 4000 Volume weighted average price: 47,00 EUR

Orion Corporation

Timo Lappalainen President and CEO

Olli Huotari SVP, Corporate Functions

                                                

Publisher:
Orion Corporation
Communications
Orionintie 1A, FI-02200 Espoo, Finland
http://www.orion.fi/en
http://www.twitter.com/OrionCorpIR

Orion is a globally operating Finnish pharmaceutical company – a builder of well-being. Orion develops, manufactures and markets human and veterinary pharmaceuticals and active pharmaceutical ingredients. The company is continuously developing new drugs and treatment methods. The core therapy areas of Orion’s pharmaceutical R&D are oncology and pain. Orion’s net sales in 2021 amounted to EUR 1,041 million and the company had about 3,350 employees at the end of the year. Orion’s A and B shares are listed on Nasdaq Helsinki.